Testosterone inhalation - Aradigm Corporation
Latest Information Update: 26 Apr 2007
At a glance
- Originator Aradigm Corporation
- Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Eye disorder therapies; Hormonal replacements; Small molecules; Testosterone congeners
- Mechanism of Action Testosterone agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Female testosterone deficiency
Most Recent Events
- 15 Mar 2016 Biomarkers information updated
- 20 Jan 2003 Phase-I clinical trials in Female testosterone deficiency in Australia (Inhalation)